Prognostic factors and efficacy of human intravenous immunoglobulin G in dogs with idiopathic immune-mediated hemolytic anemia: a retrospective study
Korean Journal of Veterinary Research
; : 139-145, 2016.
Article
in English
| WPRIM (Western Pacific)
| ID: wpr-94486
Responsible library:
WPRO
ABSTRACT
This study was conducted to determine the effect of treatment with intravenous human immunoglobulin G (hIVIgG) on outcome in dogs with idiopathic immune-mediated hemolytic anemia (IMHA), and to identify prognostic variables that determine outcome in affected dogs. Thirty-seven dogs that met the inclusion criteria were enrolled in a retrospective study. The dogs were categorized into two groups based on their having received hIVIgG. There was no significant difference in survival between the hIVIgG group and the non-hIVIgG group. Mortality during hospitalization and at 1 month, 1 year, or 2 years after discharge was not significantly different between the hIVIgG and the non-hIVIgG groups. Hemoglobinuria was significantly less prevalent in dogs that lived more than 1 year than in those who lived less than 1 year, and was less prevalent in dogs that lived more than 2 years than in those who lived less than 2 years. However, there was no difference in the presence of hemoglobinuria between dogs that lived less than 1 month and those that lived more than 1 month. Overall, there was no evidence of a beneficial effect of hIVIgG in dogs with idiopathic IMHA.
Full text:
Available
Health context:
SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases
Health problem:
Other Hemoglobinopathies and Hemolytic Anaemias
Database:
WPRIM (Western Pacific)
Main subject:
Immunoglobulin G
/
Immunoglobulins
/
Retrospective Studies
/
Mortality
/
Hemoglobinuria
/
Hospitalization
/
Anemia, Hemolytic
/
Anemia, Hemolytic, Autoimmune
Type of study:
Observational study
/
Prognostic study
Limits:
Animals
/
Humans
Language:
English
Journal:
Korean Journal of Veterinary Research
Year:
2016
Document type:
Article